FDA · Life Science & Pharma: GxP - CSV & Data Integrity
General Principles of Software Validation (FDA guidance)
Final CSV · Guidance Medical Device Item Related to CSV Last verified: not yet · Source last checked 3 Nov 2026
- Issued by
- FDA
- Category
- CSV
- Sub Category
- Guidance
- Legal weight
- Guidance & Q&A
- Reuse
- Public domain
FDA's long-standing guidance on the general principles of validating software, mainly for medical devices.
How to read this page
- The line under the title explains in plain words what this item is for. The coloured label beside its status gives its Category, its main subject, and Sub Category, the type of document, in the same colours as the maps.
- Status comes from the latest dated event below, and each event links to its source.
- Lifecycle shows the steps so far, then any expected target. Targets are not facts.
- In plain English is our own summary, not the official text. Where we have read the document in detail, a fuller profile follows, with its context, scope, contents and key points.
- Related shows links to other documents. Select Compare to see two side by side.
Lifecycle
Solid steps have happened. A dashed step is expected, and it is not a fact. Only dated steps in our record appear here.
- Draft version 1.1 dated 9 Jun 1997
- Version 2.0 issued, superseding the 1997 draft
In plain English
FDA guidance setting out the validation principles it considers applicable to medical device software, and to software used to design, develop or manufacture medical devices.
Summary drafted with AI assistance. Not yet reviewed by the SME Reviewer. Read the official text before acting.
Context and history
FDA's General Principles of Software Validation is the long-standing reference for software validation in the device world. Version 2.0 was issued on 11 January 2002, replacing a 1997 draft. It describes validation as establishing by objective evidence that software meets user needs and intended uses, and it explains why software needs a life cycle approach.
Its ideas spread well beyond devices, and it remains the foundation that Computer Software Assurance builds on.
Who and what it applies to
Medical device software, and software used to design, develop or make medical devices, including quality system software. It addresses device manufacturers and FDA staff.
What it contains
- Section 1 Purpose
- Outlines the general validation principles FDA considers applicable.
- Section 2 Scope
- Applicability, audience, the least burdensome approach, regulatory requirements and quality system regulation versus pre-market submissions.
- Section 3 Context
- Definitions, how software differs from hardware, and the benefits of validation.
- Section 4 Principles
- Requirements, defect prevention, time and effort, software life cycle, plans, procedures, software validation after a change, validation coverage, independence, flexibility and responsibility.
- Section 5 Activities and tasks
- Life cycle tasks through planning, requirements, design, construction, testing, installation, maintenance and changes.
- Section 6 Automated process equipment and quality system software
- Validating software used in production and quality systems, including off-the-shelf software.
Key points
- Validation requires objective evidence that software meets user needs and intended use.
- Software failures are usually design errors, so a life cycle approach matters.
- Changes need validation appropriate to their risk.
- Validation effort should match risk.
- Independence in review is valued.
- Users of off-the-shelf software remain responsible for validating it for their use.
In practice
General reading, not advice. This is drafted with AI and may not fit your situation. It does not replace the official text, your own quality system or qualified advice, and an inspector may take a different view.
- Read this with CSA, since CSA changes emphasis rather than its principles.
- Keep requirements traceable, which supports both approaches.
Read from the source document on 1 Nov 2026. This is our own description, not the official text. Check the full dated history in the change log below.
Change log
Key dated events only, not a complete history. Status after is the status once that event happened. Event kinds explained
| Date | Event | Status after | Source |
|---|---|---|---|
| 11 Jan 2002 | Version 2.0 issued, superseding the 1997 draft | Final | Source for Version 2.0 issued, superseding the 1997 draft |
| 9 Jun 1997 | Draft version 1.1 dated 9 Jun 1997 | Draft | Source for Draft version 1.1 dated 9 Jun 1997 |
Related
How other documents connect to this one. Links explained
- Complemented by FDA CSA guidance· Compare with FDA CSA guidance Unverified link
- Related to Part 11 scope guidance· Compare with Part 11 scope guidance Unverified link
- Related to FDA blood system validation· Compare with FDA blood system validation Unverified link
Official source
The official text always prevails over anything on this site.
Source: FDA. Public domain.
Stay updated
Newsletter signup opens at launch.